Pharsight Corporation Releases PKS(R) Validation Suite(TM)

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services designed to optimize clinical drug development, today announced that it has released Pharsight Knowledgebase Server (PKS) Validation Suite. The Validation Suite enables rapid and reliable validation of PKS 3.0 installations using a combination of automated and manual tests. The Validation Suite provides templates for validation life cycle documents, such as a Validation Plan, Test Plan, and Validation Summary Report, and inserts automated test results into a Validation Run Report.

“Computer systems validation is a crucial aspect of compliance and can be a rate-limiting step in the installation of clinical data management and analysis systems,” said Shawn O’Connor, President and Chief Executive Officer of Pharsight. “The PKS Validation Suite streamlines the validation process for Pharsight’s PKS product, resulting in a shorter path to the efficiencies and reliability advantages that PKS offers. The Validation Suite products, for both PKS and WinNonlin, are indicative of Pharsight’s commitment to enabling the deployment of its products within the rigorously regulated clinical environment.”

About Pharsight Corporation

Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers’ development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at www.pharsight.com.

Safe Harbor

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the anticipated development and performance of Pharsight’s products and the expected benefits to customers from the use of Pharsight’s products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight’s products and services, changes in Pharsight’s research and development focus or operating strategies, the failure to develop new products and services or to keep pace with technological changes, delays in the release of new products and services, the failure of Pharsight’s products and services to obtain anticipated levels of customer acceptance or to meet customers’ expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.

NOTE: Pharsight, Pharsight Knowledgebase Server, PKS, PKS Validation Suite, WinNonlin are trademarks or registered trademarks of Pharsight Corporation.

Pharsight Corporation

CONTACT: investors, Douglas Sherk or Jennifer Beugelmans, +1-415-896-6820,or media, Steve DiMattia, +1-646-277-8706, all of EVC Group

MORE ON THIS TOPIC